A known fact is that between 15% to 35% of men who have surgery as their primary treatment after diagnosis of prostate cancer will experience a biochemical recurrence (BCR). The authors of a presentation, Michael B. Williams, MD, et al. presented at the American Urological Association Mid-Atlantic Section - 67th Annual Meeting - October 1 [...]
Today the movie version of Maurice Sendak's 1963 children’s picture book, “Where the Wild Things Are” opens in theaters. When the book was first published, many people complained that it was too scary. Sendak’s response was simple, he said just don’t read it. Sometimes, whether you read a book or watch a movie is not [...]
I have experienced both hope and despair. In my life, they are inextricably intertwined with each other. I have come to understanding that I must celebrate both life’s low points as well as its high points. I have heard on four separate occasions, “Joel, you have cancer.” I have struggled through the impact of hearing [...]
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that it's experimental product, OGX-011, also known as custirsen sodium, received fast track designation from the U.S. Food & Drug Administration (FDA) for the treatment of progressive metastatic prostate cancer in combination with first-line docetaxel treatment (chemotherapy). OGXI had previously received this same designation for second-line docetaxel treatment with OGX-011 [...]
Concerned that your diabetes could making you more vulnerable to dying from prostate cancer? Yes, diabetes sufferers should be concerned about a potential shorter life span, but not as of a result of prostate cancer (CaP). In the Journal of Clinical Oncology (September 10, 2008), Dr. Matthew Smith and his colleagues reported on the association [...]